---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-003549"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:24:27.913433+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Catalyst settles FIRDAPSE patent suit with Teva; generic entry barred until Feb 2035

## Summary
- Teva agrees not to market generic FIRDAPSE in the U.S. before February 25, 2035, if FDA approved.
- All ongoing FIRDAPSE patent litigation between Catalyst/SERB and Teva will be terminated.
- Litigation against remaining defendants Hetero (all patents) and Lupin (2037 patent) is ongoing.
- Confidential license agreement to be submitted to FTC and DOJ for review.

## SEC filing metadata
- accession: 0001193125-25-003549
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312525003549/0001193125-25-003549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312525003549/d890025d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-003549
- JSON: https://secwatch.observer/filing/0001193125-25-003549.json
- Plain text: https://secwatch.observer/filing/0001193125-25-003549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.